JP7495138B2 - ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法 - Google Patents

ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法 Download PDF

Info

Publication number
JP7495138B2
JP7495138B2 JP2021510959A JP2021510959A JP7495138B2 JP 7495138 B2 JP7495138 B2 JP 7495138B2 JP 2021510959 A JP2021510959 A JP 2021510959A JP 2021510959 A JP2021510959 A JP 2021510959A JP 7495138 B2 JP7495138 B2 JP 7495138B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
myocardial infarction
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534221A (ja
JP2021534221A5 (https=
JPWO2020047186A5 (https=
Inventor
バート ダブリュー． オマリー，
デイビッド マイケル ロナルド，
ヨンチェン ソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2021534221A publication Critical patent/JP2021534221A/ja
Publication of JP2021534221A5 publication Critical patent/JP2021534221A5/ja
Publication of JPWO2020047186A5 publication Critical patent/JPWO2020047186A5/ja
Priority to JP2024080082A priority Critical patent/JP7777263B2/ja
Application granted granted Critical
Publication of JP7495138B2 publication Critical patent/JP7495138B2/ja
Priority to JP2025153392A priority patent/JP2025183370A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2021510959A 2018-08-29 2019-08-29 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法 Active JP7495138B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024080082A JP7777263B2 (ja) 2018-08-29 2024-05-16 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法
JP2025153392A JP2025183370A (ja) 2018-08-29 2025-09-16 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862724281P 2018-08-29 2018-08-29
US62/724,281 2018-08-29
US201962825358P 2019-03-28 2019-03-28
US62/825,358 2019-03-28
PCT/US2019/048703 WO2020047186A1 (en) 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024080082A Division JP7777263B2 (ja) 2018-08-29 2024-05-16 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法

Publications (4)

Publication Number Publication Date
JP2021534221A JP2021534221A (ja) 2021-12-09
JP2021534221A5 JP2021534221A5 (https=) 2022-09-02
JPWO2020047186A5 JPWO2020047186A5 (https=) 2022-09-02
JP7495138B2 true JP7495138B2 (ja) 2024-06-04

Family

ID=67982135

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021510959A Active JP7495138B2 (ja) 2018-08-29 2019-08-29 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法
JP2024080082A Active JP7777263B2 (ja) 2018-08-29 2024-05-16 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法
JP2025153392A Pending JP2025183370A (ja) 2018-08-29 2025-09-16 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024080082A Active JP7777263B2 (ja) 2018-08-29 2024-05-16 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法
JP2025153392A Pending JP2025183370A (ja) 2018-08-29 2025-09-16 ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法

Country Status (7)

Country Link
US (4) US10875841B2 (https=)
EP (1) EP3843843A1 (https=)
JP (3) JP7495138B2 (https=)
CN (2) CN120136844A (https=)
AU (2) AU2019333119B2 (https=)
CA (1) CA3110839A1 (https=)
WO (1) WO2020047186A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120136844A (zh) * 2018-08-29 2025-06-13 贝勒医学院 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法
KR20230093329A (ko) 2020-10-28 2023-06-27 베이롤 칼리지 오브 메드신 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화
WO2025240566A1 (en) * 2024-05-17 2025-11-20 Baylor College Of Medicine Small molecule steroid receptor coactivator stimulators for use in repairing tissue

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011074024A (ja) 2009-09-30 2011-04-14 Shiseido Co Ltd ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物
CN102153508A (zh) 2010-10-08 2011-08-17 福建医科大学 3,5-(e)-二亚苄基-n-环丙基哌啶-4-酮及其在制备治疗抗肿瘤药物中的应用
CN103181922A (zh) 2013-04-02 2013-07-03 温州医学院 一类含哌啶酮的单羰基姜黄素类化合物在制备抗炎药物中的应用
WO2016109470A1 (en) 2014-12-30 2016-07-07 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
CN106083704A (zh) 2016-06-06 2016-11-09 福建医科大学 3,5‑(E)‑ 二芳亚甲基‑N‑环丙基哌啶‑4‑酮类化合物作为Hsp90抑制剂的应用
WO2017062751A1 (en) 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
CA2393440A1 (en) 1999-12-03 2001-06-07 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20070010488A1 (en) 2005-04-13 2007-01-11 Khairia Youssef Compounds for modulating cell proliferation
CN102381951B (zh) 2007-01-22 2013-09-04 温州医学院生物与天然药物开发中心有限公司 含环己酮的姜黄素单羰基结构类似物及其用途
EP2170311A4 (en) 2007-05-16 2011-10-19 Avalon Pharmaceuticals COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
US20100197584A1 (en) 2007-07-27 2010-08-05 Research Foundations of the City University of- New York Use of curcumin to block brain tumor formation in mice
WO2009144220A1 (en) 2008-05-29 2009-12-03 Universite Libre De Bruxelles Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
US8420118B2 (en) * 2009-09-10 2013-04-16 The Board Of Regents Of The University Of Oklahoma Anionic lipids and lipid nano-structures and methods of producing and using same
WO2011029359A1 (zh) 2009-09-12 2011-03-17 温州医学院 含11β-羟基甾体脱氢酶1双重调节剂的药物及其应用
WO2011127333A2 (en) 2010-04-09 2011-10-13 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012021692A1 (en) 2010-08-11 2012-02-16 Rutgers, The State University Of New Jersey Curcumin analogs and methods of use thereof
CN103012088B (zh) 2012-11-28 2017-01-11 江苏药兴医药股份有限公司 α-(3,5-二甲氧基苯亚甲基)-α'-烃基亚甲基环酮及其制备方法
ITMI20130075A1 (it) 2013-01-21 2014-07-22 Altergon Sa Combinazione orale per la prevenzione e il trattamento di patologie vescicali, pelviche e dell¿apparato uro-genitale
EP3713916A1 (en) * 2017-11-20 2020-09-30 Kiakos, Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
CN120136844A (zh) * 2018-08-29 2025-06-13 贝勒医学院 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011074024A (ja) 2009-09-30 2011-04-14 Shiseido Co Ltd ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物
CN102153508A (zh) 2010-10-08 2011-08-17 福建医科大学 3,5-(e)-二亚苄基-n-环丙基哌啶-4-酮及其在制备治疗抗肿瘤药物中的应用
CN103181922A (zh) 2013-04-02 2013-07-03 温州医学院 一类含哌啶酮的单羰基姜黄素类化合物在制备抗炎药物中的应用
WO2016109470A1 (en) 2014-12-30 2016-07-07 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
WO2017062751A1 (en) 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
CN106083704A (zh) 2016-06-06 2016-11-09 福建医科大学 3,5‑(E)‑ 二芳亚甲基‑N‑环丙基哌啶‑4‑酮类化合物作为Hsp90抑制剂的应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Albert, Francisc M.; Bornaz, Constantin，The synthesis of some 1-cyclohexyl-3,5-bis-arylidene-4-piperidones，Revistade Chimie (Bucharest, Romania) ，1975年，26(11),，902-4
Ge, Hai-Xia; et.al，Inhibitory effect of curcumin analogs on tissue factor procoagulant activity and their preliminary structure-activity relationships，Medicinal Chemistry Research ，2013年，22(7)，3242-3246
Liu, Yang; et.al，Synthesis and antitumor activity in vitro of 3,5-bis(substituted-benzylidene)-1-cyclopropylpiperidin-4-ones，Zhongguo Yaowu Huaxue Zazhi ，2011年，21(4),，262-266
Lonard, David M.; O'Malley, Bert W.，Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer，Clinical Cancer Research，2016年，22(22),，5403-5407
REGISTRY(STN)[online]，2010年09月16日，p.1，[検索日] 2023.07.13 CAS登録番号：1241694-59-6
Zhao, Ran; et.al，EF24 suppresses invasion and migration of hepatocellular carcinoma cells in vitro via inhibiting the phosphorylation of Src，BioMed Research International ，2016年，8569684/1-8569684/10

Also Published As

Publication number Publication date
JP2024102352A (ja) 2024-07-30
EP3843843A1 (en) 2021-07-07
AU2019333119B2 (en) 2025-06-05
JP2021534221A (ja) 2021-12-09
CN120136844A (zh) 2025-06-13
US20230357200A1 (en) 2023-11-09
CN112955217B (zh) 2025-04-08
AU2025226726A1 (en) 2025-09-25
CN112955217A (zh) 2021-06-11
US20250282755A1 (en) 2025-09-11
AU2019333119A1 (en) 2021-03-18
US12338229B2 (en) 2025-06-24
JP2025183370A (ja) 2025-12-16
WO2020047186A1 (en) 2020-03-05
US10875841B2 (en) 2020-12-29
JP7777263B2 (ja) 2025-11-28
US11708350B2 (en) 2023-07-25
US20200071300A1 (en) 2020-03-05
US20210115017A1 (en) 2021-04-22
CA3110839A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
JP7777263B2 (ja) ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法
Mohammadi et al. Cancer Textbook 4:(Cancer Treatment and Ovarian Cancer)
RU2637372C2 (ru) Средство для лечения фиброза кишечника
Debnath et al. Aryl quinolinyl hydrazone derivatives as anti-inflammatory agents that inhibit TLR4 activation in the macrophages
US20220280484A1 (en) Novel use
EP3600301B1 (en) Kdm4 inhibitors
EP3419666A1 (en) Alpha-1-adrenergic receptor agonist therapy
Li et al. Deletion of ASPP1 in myofibroblasts alleviates myocardial fibrosis by reducing p53 degradation
Truong et al. Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge
KR101191958B1 (ko) Ｔｌｅ1 억제제를 유효성분으로 함유하는 활액막 육종 예방 및 치료용 약학적 조성물
US20100113602A1 (en) Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
CN111840557A (zh) 磷酸二酯酶4抑制剂的用途
WO2018017589A1 (en) Compounds for targeting cancer stem cells
JP7283699B2 (ja) 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
JP7759032B2 (ja) 脳血管攣縮抑制剤
WO2025162246A1 (zh) 防治多发性骨髓瘤的甲磺酸普依司他及其类似物联合用药物及其用途
Alizoti et al. JAK1/2 inhibitor ruxolitinib reduces aggregates in cardiac proteinopathy
Wang et al. BACH2 ameliorates cell apoptosis and autophagy as a molecular switch of BCL-2/Beclin-1 complex in myocardial infarction
Pan et al. Fabkin Promoted Osteoclasts Mature and Bone Loss in OVX‐Induced Osteoporosis Mice
JP2023059508A (ja) 悪性中皮腫の治療薬
CN116173040A (zh) Xmd17109作为arih1激动剂的用途
WO2020241778A1 (ja) 線維化を抑制する医薬組成物
WO2003019144A2 (en) METHODS AND COMPOSITIONS FOR SCREENING, DIAGNOSING, OR TREATING NF-λB RELATED DISEASE
WO2006124727A2 (en) Compositions and methods useful in preventing cardiac hypertrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220825

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240417

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240516

R150 Certificate of patent or registration of utility model

Ref document number: 7495138

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150